POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison
Value in Health(2022)
Abstract
ICARIA trial (NCT02990338) evaluated isatuximab (Isa) plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM) after ≥two prior lines of therapy (LOTs). In the absence of head-to-head trials, we compared efficacy and safety of IsaPd versus daratumumab+Pd (DPd) [APOLLO; NCT03180736], using a matching-adjusted indirect comparison (MAIC).
MoreTranslated text
Key words
multiple myeloma,isatuximab plus pomalidomide,dexamethasone,matching-adjusted
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined